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Abstract
Objectives: To study whether subjects with a molecular genetic diagnosis of familial hypercholesterolemia (FH) or familial
defective apoB-100 (FDB) are being adequately treated.
Design: A questionnaire regarding medical history was sent to 2611 subjects who had been provided with a molecular
genetic diagnosis of FH or FDB, and a blood sample was obtained for lipid measurements.
Results: 956(36.6%)ofthe2611subjectsparticipated.Themeanageforstartinglipid-loweringtherapywas33.4(612.1)years.
Among those below 18 years of age, only 20.4% were on lipid-lowering drugs, whereas 89.1% of those aged 18 and above
were on lipid-lowering drugs. The mean levels of total serum cholesterol and LDL-cholesterol were 5.7 (61.5) mmol/l and 3.9
(61.3) mmol/l, respectively. Among those who were on lipid-lowering drugs, 29.0% and 12.2% had levels of LDL cholesterol
below 3.0 mmol/l and 2.6 mmol/l, respectively. Only 47.3% of the 956 subjects were considered as being adequately treated
largely due to a failure to titrate their drug regimens.From the use of cholesterol-years score, lipid-lowering therapy must start
before the age of 20 in order to prevent the subjects from contracting premature coronary heart disease.
Conclusion: The majority of FH/FDB subjects are being diagnosed late in life and are not being adequately treated. In order
to prevent them from contracting premature coronary heart disease, it is key that levels of LDL cholesterol are normalized
from a young age and that sufficient doses of lipid-lowering drugs are being used.
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Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant
disorder caused by mutations in the low density lipoprotein (LDL)
receptor gene [1]. As a result of defective cell-surface LDL receptors,
clearance of LDL from plasma is reduced leading to increased
plasma levels of LDL cholesterol and total cholesterol [1]. Those
who are heterozygotes have values for total serum cholesterol in the
range of 7 to 15 mmol/l, whereas those who are homozygotes have
values for total serum cholesterol in the range of 20 to 25 mmol/l
[1]. As a result of the increased cholesterol levels, FH subjects are at
an increased risk of contracting premature coronary heart disease
(CHD) [1,2].FH isone ofthe mostcommongeneticdisorders with a
prevalenceofheterozygotes of approximately 1/500 inmostwestern
countries [3,4]. Thus, FH has a significant impact on public health
and it has been estimated that FH heterozygotes constitute
approximately 5% of those with premature CHD [5,6].
However, efficient lipid-lowering therapy is available for FH
heterozygotes which may normalize their levels of total serum
cholesterol and LDL cholesterol [7]. The general experience,
however, is that too few patients are being treated, and those who
are being treated, are not being adequately treated [8–13].
Moreover, lipid-lowering therapy generally starts late in life at a
time when advanced atherosclerosis has already developed [13]. It
is believed that a major cause for these treatment failures is
difficulties in diagnosing FH by the use of the clinical diagnostic
criteria consisting of autosomal dominant hypercholesterolemia
and presence of premature CHD and xanthomas [1,14–16]. The
sensitivity of these criteria is particularly low in children/
adolescents who do not have manifest CHD nor xanthomas. In
contrast to the relatively vague clinical criteria, a specific diagnosis
can be obtained by identifying a mutation in the LDL receptor
gene by molecular genetic methods [1,10,16].
Two genocopies of FH have been identified. One is familial
defective apoB-100 (FDB) which is caused by mutation R3500Q in
the apoB-100 gene [17], and the other is FH3 which is caused by
gain-of-function mutations in the proprotein convertase subtilisin/
kexin type 9 (PCSK9) gene [18]. Among subjects provided with a
molecular genetic diagnosis of autosomal dominant hypercholes-
terolemia in Norway, 95% are FH heterozygotes, 3% are FDB
heterozygotes and 2% are FH3 heterozygotes (unpublished data).
To study whether a molecular genetic diagnosis of autosomal
dominant hypercholesterolemia secures that the subjects become
adequately treated, we have performed a questionnaire-based
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have been provided with a molecular genetic diagnosis of FH or
FDB during a 10-year period in Norway.
Materials and Methods
Subjects
During the period 1998–2008, 2611 subjects have been
provided with a molecular genetic diagnosis of FH or FDB in
our laboratory. This had been done by the use of various
mutations detection methods to screen for mutations in the LDL
receptor gene (NG_009060) and apoB-100 gene (NG_011793),
respectively. The subjects were invited to participate in a follow-up
study to have their current therapies evaluated. Thus, the main
aim of the study was to secure that subjects who had been
diagnosed with FH or FDB, were being adequately treated. In
order to participate, the subjects would have to answer a
questionnaire for assessment of their risk profile and to have a
non-fasting blood sample drawn for lipid analyses. The blood
samples were sent to Department of Medical Biochemistry, Oslo
University Hospital Rikshospitalet for analysis, and the report was
sent to us. Values for LDL cholesterol were obtained by direct
measurement and not calculated according to the formula of
Friedewald et al. [19]. Thus, measurements of values for LDL
cholesterol were not dependent on fasting blood samples. Because,
the goal of this initiative was to secure that patients were being
adequately treated, it did not need approval of an ethics committee
as confirmed by a statement of August 30, 2006 from Regional
Committee for Research Ethics in Southern Norway. Thus, the
ethics committee specifically waived the need to collect written
informed consent.
Evaluation of the adequacy of the current lipid-lowering
therapy
Evaluation of the adequacy of the current lipid-lowering therapy
was based upon assessment of the subject’s global risk for CHD from
medical and family histories obtained at the time of genetic testing
and from information in the questionnaire. Several factors were
considered for this evaluation such as age of the subject, family
history, lipid levels before lipid-lowering therapy was started, age for
start of lipid-lowering therapy, number of years on lipid-lowering
therapy, lipid profile on lipid-lowering therapy, presence of manifest
CHD such as myocardial infarction or angina pectoris and the
presenceofadditional riskfactors suchas smoking and hypertension.
Based upon the subject’s risk profile which was established by the
two authors who are well experienced with genetic lipid disorders,
the current lipid profile was evaluated and thelipid-lowering therapy
was classified as being adequate or not. No defined algorithm was
being used for this classification, as there is no validated algorithm
that considers all relevant parameters for assessing the global risk for
CHD in FH/FDB heterozygotes. However, with respect to the lipid
profile the values for total serum cholesterol and LDL cholesterol
should generally be below 5 mmol/l and 3 mmol/l, respectively for
the therapy to be considered adequate.
Results
Of the 2611 subjects with a molecular genetic diagnosis of FH or
FDB who had been invited to participate, 956 (36.6%) actually
answered the questionnaire and had a blood sample drawn for lipid
measurements. Descriptive statistics of the participants are given in
Table 1. There were 534 females and 422 males and there was a
clear tendency towards relative more females in the higher age
groups.This probablyreflectsthatfemalesdevelopCHDlaterinlife
than males. The mean age of the subjects was 44.3 (617.0) years.
The youngest was 5 and the oldest was 77 years old. Molecular
genetic testing with respect to FH or FDB had been performed at a
mean age of 39.8 (617.3) years, and 35 subjects were heterozygous
for the R3500Q mutation in the apoB-100 gene and 921 were
heterozygous for one of 88 different mutations in the LDL receptor
gene. 266 (27.8%) subjects were index patients and 690 (72.2%) had
been diagnosed by cascade genetic screening.
Table 1. Characteristics of subjects with FH or FDB of different age groups who participated in the follow-up study to evaluate
their treatment status.
Age groups
All 5–14 15–24 25–34 35–44 45–54 55–64 .65
N (males/females) 422/534 29/21 54/54 37/64 94/100 82/117 158/226 50/169
Age (years) 44.3 (617.0) 12.2 (62.1) 18.7 (62.9) 29.9 (63.1) 39.8 (62.8) 49.2 (62.8) 54.1 (65.8) 69.1 (63.3)
Age of molecular
genetic testing (years)
39.8 (617.3) 8.8 (62.9) 13.7 (63.7) 25.4 (64.0) 35.1 (63.5) 44.3 (63.8) 49.4 (66.6) 65.4 (64.0)
Index patients (%) 27.8 12.0 10.2 29.7 35.1 34.5 33.6 18.5
Age for measurement
of total serum cholesterol
without lipid-lowering
therapy (years)
27.4 (613.3) 6.5 (63.1) 8.9 (64.8) 18.8 (66.0) 24.5 (67.3) 29.4 (68.8) 33.0 (610.0) 41.0
(612.2)
Value for total serum
cholesterol without
lipid-lowering therapy (mmol/l)
10.5 (62.5) 8.2 (61.5) 8.5 (61.6) 9.1 (61.8) 10.1 (62.5) 11.0 (62.4) 11.1 (62.4) 11.9 (62.4)
Age for starting lipid-lowering
drugs (years)
33.4 (612.1) 10.5 (61.1) 15.4 (63.1) 22.0 (65.1) 29.5 (66.5) 33.7 (68.3) 37.4 (69.7) 45.3
(611.7)
Manifest CHD
# (%) 16.1 0 0 1.0 9.8 14.7 20.2 42.7
Current smoker (%) 13.5 0 9.3 9.0 13.9 20.8 19.3 7.6
Hypertension (%) 12.1 0 1.9 3.2 5.3 11.2 15.2 35.1
#Myocardial infarction, angina pectoris, coronary artery bypass graft or percutaneous coronary intervention.
doi:10.1371/journal.pone.0016721.t001
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without lipid-lowering therapy was 27.4 (613.3) years, and the
reported value for total serum cholesterol was 10.5 (62.5) mmol/l
(Table 1). The relationship between age and levels of total serum
cholesterol before lipid-lowering therapy was started, is shown in
Fig. 1. 84.8% of the subjects had used lipid-lowering drugs, and the
mean age for starting lipid-lowering therapy was 33.4 (612.1) years
(Table 1). 16.1% reported that they had manifest CHD, 13.5%
were current smokers and 12.1% had hypertension.
At the follow-up, 82.3% were on lipid-lowering drugs (Table 2).
However, among those below age 18, only 20.4% were on lipid-
lowering drugs, whereas 89.1% of those aged 18 and above were on
lipid-lowering drugs. Among the subjects aged 30 and below or 40 and
below, 45.3% and 62.9%, respectively were on lipid-lowering drugs.
The levels of total serum cholesterol and LDL cholesterol
measured at the follow-up for the 956 subjects, were 5.7 (61.5)
mmol/l and 3.9 (61.3) mmol/l, respectively (Table 2). Thus,
compared to the reported levels of total serum cholesterol before
lipid-lowering therapy were started, a reduction in the levels of total
serum cholesterol of 45.7% had been achieved. The mean value for
total serum cholesterol in the 772 subjects who wereon lipid-lowering
therapy, was 5.4 (61.2) mmol/l (LDL cholesterol: 3.6 (61.2) mmol/
l), and these subjects had achieved a reduction in levels of total serum
cholesterol of 49.5%. Among the 772 subjects who were on lipid-
lowering therapy, 34.9% were on atorvastatin monotherapy with a
mean dosis of 53 mg, and 29.3% were on simvastatin monotherapy
with a mean dosis of 43 mg. 22.5% were on combination therapy
with atorvastatin and ezetimibe, 4.8% were on combination therapy
with simvastatin and ezetimibe and 3.7% were on combinatation
therapy with three or more lipid-lowering drugs.
Among those who were on lipid-lowering therapy, only 29.0%
had an LDL cholesterol value below 3.0 mmol/l, and only 12.2%
had an LDL cholesterol value below 2.6 mmol/l. Among all 956
subjects, 52.7% were considered as being inadequately treated
(Table 2). The levels for total serum cholesterol and LDL
cholesterol among those whose lipid-lowering therapies were
considered as being inadequate, were 6.6 (61.4) mmol/l and 4.7
(61.3) mmol/l, respectively. These levels were significantly higher
than the corresponding levels of 4.9 (61.1) mmol/l (p,0.0001)
and 3.1 (60.9) mmol/l (p,0.0001), respectively in those whose
therapy was considered as being adequate.
There was a wide variation regarding the age both for diagnosis
and for the start of lipid-lowering therapy (Table 1). Some had
been diagnosed and put on lipid-lowering therapy in their first or
second decades, whereas others had not been diagnosed and put
on lipid-lowering therapy until their sixth or seventh decades. The
later in life lipid-lowering therapy starts, and the higher the total
serum cholesterol level, the more atherosclerosis is present [20].
The cholesterol-years score can be used as a measurement of the
atherosclerosis burden [21]. To determine the cholesterol-years
score, the value for total serum cholesterol is multiplied by the age
of the subject to generate the ‘‘area under the curve’’ in Fig. 1.
If the mean value for total serum cholesterol in the 772 subjects who
were on lipid-lowering therapy at the follow-up of 5.4 (61.2) mmol/l,
is being used as a fixed value for total serum cholesterol on lipid-
lowering therapy, the data in Fig. 1 can be used to calculate the
cholesterol-years score for subjects who start lipid-lowering therapy at
different ages until the seventh decade. Whereas, a non-FH/FDB
subject with a value for total serum cholesterol of 5.4 mmol/l until the
age of 60 will have a cholesterol-years score of 324 mmol years/l, an
FH/FDB subject who does not start lipid-lowering therapy before the
age of 60, will have a cholesterol-years score of 642 mmol years/l
(Fig. 1). However, an FH/FDB subject who starts lipid-lowering
therapy at the age of 10 and achieves a total serum cholesterol level of
5.4 mmol/l, will have a cholesterol-years score of 350 mmol years/l at
the age of 60 (Fig. 1). For subjects who starts lipid-lowering therapy at
the age of 10 or 20 years, treatment values for total serum cholesterol
must be 4.9 mmol/l or 3.9 mmol/l, respectively in order to achieve a
cholesterol-years score of 324 mmol years/l at the age of 60.
Discussion
In this study we have determined the treatment status of FH/FDB
patients provided with a molecular geneticdiagnosis during the period
1998–2008 in Norway. The main finding was that even though the
subjects had obtained a specific molecular genetic diagnosis, only
47.3% were considered as being adequately treated. This finding
reflects that submaximal doses of lipid-lowering drugs were used with
mean doses of atorvastatin and simvastatin monotherapies of 53 mg
and 43 mg, respectively. Thus, there is a need to educate physicians in
order to improve the lipid-lowering therapy in FH/FDB patients.
Moreover, our study has shown that lipid-lowering therapy had been
s t a r t e dl a t ei nl i f ea tam e a na g eo f3 3 . 4( 612.1) years. This partly
reflects that the mean age for the first measurement of total serum
cholesterol was 27.4 (613.3) years and that the mean age for the
molecular genetic diagnosis was 39.8 (617.3) years. Thus, there is a
need to diagnose these subjects earlier in life.
However, some caution should be exerted when interpreting our
findings since only 36.6% of those who were invited to participate,
actually did participate. The participants could therefore in theory
represent a selected group of patients who could be particularly well
or particularly poorly treated. Moreover, because information
regarding medical history was obtained from the patients themselves
through a questionnaire, and not extracted from medical files, some
uncertainties may exist regarding the quality of this information.
Among those aged 18 and above, 89.1% were on lipid-lowering
drugs. For comparison 96% of adult Dutch FH patients were on
Figure 1. Cholesterol-years score in FH/FDB heterozygotes.
Levels of total serum cholesterol in FH/FDB heterozygotes in different
age groups before lipid-lowering therapy is started are plotted against
age of the subjects (data from Table 1). Linear regression (y=0.111x +
7.408) has been used to generate the relationship between levels of
total serum cholesterol and age from birth until the age of 60.
Cholesterol-years scores for subjects who are put on lipid-lowering
therapy at different decades and achieved a total serum cholesterol
level of 5.4 mmol/l, are indicated.
doi:10.1371/journal.pone.0016721.g001
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that the Dutch patients were treated at specialized out-patient
clinics, whereas the majority of the Norwegian patients were being
treated by general practitioners. Among the Norwegian patients
who were on lipid-lowering drugs, 29.0% and 12.2% had levels of
LDL cholesterol below 3.0 mmol/l and 2.6 mmol/l, respectively.
Thus, the majority of Norwegian FH/FDB subjects are being
diagnosed late in life and are not being adequately treated. 16% of
the subjects in our study had a history of CHD which is similar to
that of 17% found among Dutch FH heterozygotes [22].
The American Academy of Pediatrics has recommended that
screening for FH should be performed at an age of 2–10 years, and
that lipid-lowering therapy may start from the age of 8 [23]. These
recommendations reflect that the atherosclerotic lesions are largely
reversible before the age of 10 in contrast to the calcified lesions
seen in untreated middle-aged FH/FDB subjects. Moreover, it has
been well documented that lipid-lowering therapy from late
childhood/adolescence is effective, safe and well tolerated [24].
The cholesterol-years score in Fig. 1 illustrates the importance of
starting lipid-lowering therapy at a young age. This score has been
found to be a predictor of aortic stenosis [25,26] and is correlated
with the severity of atherosclerosis in carotid arteries in FH
heterozygotes [27,28]. It also correlates well with the severity of
calcific atherosclerosis and angina pectoris in FH homozygotes with
an apparent threshold for calcific atherosclerosis at a cholesterol-
years score of 182 mmol l/years [21]. If lipid-lowering therapy starts
at the age of 10, and a realistic treatment value for total serum
cholesterol of 4.9 mmol/l is achieved, the cholesterol-years score
until the age of 60 is 324 mmol year/l. This score is identical to that
ofanon-FH/FDBsubjectwhohashadatotalserumcholesterollevel
of 5.4 mmol/l during the same periode.For comparison, the median
levelsof total serum cholesterol inthe Nordiccountries for subjects in
their fourth, fifth and sixth decades are 4.8 mmol/l, 5.2 mmol/l and
5.6 mmol/l, respectively [www.furst.no/norip/]. If lipid-lowering
therapy starts at the age of 20, a total serum cholesterol value of
3.9 mmol/l is required to achieve a cholesterol-years score of
324 mmol year/l at the age of 60. Such a cholesterol value will
probably only be achievable in a minority of FH/FDB patients. If
lipid-lowering therapy starts after the second decade, it is not realistic
to achieve sufficiently low levels of total serum cholesterol and LDL
cholesteroltoachievea riskof CHD at the age of 60similar to that of
a non-FH/FDB subject. Thus, for subjects diagnosed after the age of
20, maximum tolerated doses of combination therapies should be
prescribed in order to reduce the risk of CHD.
The question then is how secure that patients with FH/FDB are
being diagnosed early in life. Several strategies have been
discussed, including population-based cholesterol screening of
children which has not been recommended by any pediatric
organizations [29]. Because lipid measurements do not have the
required sensitivity and specificity and because clinical character-
istics such as xanthomas and premature CHD do not occur in
children, the diagnosis should preferentially be based on molecular
genetic testing [16]. Our recommendation which is in line with the
NICE guidelines [30] is that cholesterol screening is made
common in young adults in order to select index patients for
molecular genetic screening. Once the underlying mutation has
been identified, cascade genetic screening, which is the most cost-
effective strategy to diagnose FH/FDB patients [31-33], is being
used to diagnose children and other family members. However,
our study clearly illustrates the need for educating physicians in
order to improve the lipid-lowering therapy even in FH/FDB
patients with a molecular genetic diagnosis.
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